Vilazodone

Vilazodone is a serotonergic antidepressant. Vilazodone was approved by the FDA for use in the United States to treat major depressive disorder in 2011. The mechanism of the antidepressant effect of vilazodone is not fully understood but is thought to be related to its enhancement of serotonergic activity in the CNS through selective inhibition of serotonin reuptake. Vilazodone is also a partial agonist at serotonergic 5-HT1A receptors; however, the net result of this action on serotonergic transmission and its role in vilazodone's antidepressant effect are unknown.

Properties:

Appearance & Physical State: Light yellow solid

Density: 1.34 g/cm3

Boiling Point: 745.1ºC at 760 mmHg

Melting Point:  203-205ºC

Serotonin Transporter inhibitor Related Prodcuts:

Paroxetine hcl; Fluvoxamine maleate; Sertraline HCl; Vilazodone Hydrochloride; Milnacipran Hydrochloride; Duloxetine; Vortioxetine; Venlafaxine HCl

[1]. Cruz MP. Vilazodone HCl (Viibryd): A Serotonin Partial Agonist and Reuptake Inhibitor For the Treatment of Major Depressive Disorder. P T. 2012 Jan;37(1):28-31.

[2]. Citrome L. Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J C